Global Nuclear Medicine Therapeutics Market-Market Dynamics
The report details several driving and restraining factors for the market. Some of these are listed below.
The major factors contributing to the growth of the market are:
Increasing use of SPECT and PET analysis in radiopharmaceuticals
Increased awareness in people for radiopharmaceuticals
Ready availability of radiopharmaceuticals
Novel applications such as Alzheimer‰Ûªs
Continually expanding oncology application segment
Some of the factors restraining market growth are:
Complex FDA toxicology and other regulatory requirements
Lack of specific guidelines from the FDA for good manufacturing practices of radiopharmaceuticals
Lack of consensus for standardized image acquisition in nuclear imaging procedures
Therapeutic nuclear medicine finds its application in the treatment of various types of cancer such as lymphoma, bone metastasis, thyroid, endocrine tumors etc. Radionuclide therapy has unique promise as a vehicle for personalized treatment of cancer. Alpha emitters that use bismuth-213 and astatine-211 labeled monoclonal antibodies in patients with leukemia and brain tumor and radium- 223 are being evaluated in breast and prostate cancer patients with bone metastases. Beta emitters are currently limited to yttrium-90 and iodine-131, which are used in the treatment of non-Hodgkins lymphoma, samarium-153-EDTMP, and strontium-89-chloride for palliation of bone metastases. The market scope of preclinical and clinical research in the therapy field is much broader.
The number of therapeutic procedures in North America, Europe, and Asia-Pacific is 265, 22,195, and 271,248 for the year 2013 respectively. Talking about country-wise therapeutic procedures, the US has 262 therapeutic procedures. Developing countries like India hold strong market potential, accounting for 7475 therapeutic procedures.
The market is segmented into Beta Emitters (Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (SM-153), Rhenium-186 (RE-186), Lutetium-177 (LU-177)and Others); Alpha Emitters(Radium-223 (RA-223) & Alpharadin, Actinium-225 (AC-225), Lead-212 (PB-212)/Bismuth-212 (BI-212)and Astatine-211 (AT-211)) and Brachytherapy (Cesium-131, Iodine-125, Palladium-103 and Iridium-192), applications and geography ( North America, Europe and Asia-Pacific).
Mergers and acquisitions of small and medium-sized manufacturers to enter the overseas market is a strategy adopted by multinational players.
This Report Offers:
Market definition for the global nuclear medicine therapeutic (Alpha Emitters, Beta Emitters, and Brachytherapy) market along with identification of key drivers and restraints for the market.
Market analysis for the nuclear medicine therapeutic (Alpha Emitters, Beta Emitters, and Brachytherapy) with region-specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their market share.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
A comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.
An ideal opportunity for industry consultants and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.
Wide-ranging information provided about the leading market players and the major strategies adopted by them.
1.1 Market Definition
1.2 Market Size Estimation
2. Key Findings 3. Executive Summary 4. Market Overview
4.1 Definition of radiopharmaceuticals
4.2 Market Share Analysis
4.3 Market dynamics
4.3.1 Market Drivers
126.96.36.199 Increasing incidents of Cancer and Cardiac ailments
188.8.131.52 Increasing awareness of radiopharmaceuticals
184.108.40.206 Public Awareness
220.127.116.11 Ready availability of radiopharmaceuticals
4.3.2 Market Restraints
18.104.22.168 Shorter half-life of radiopharmaceuticals
22.214.171.124 High capital investment
126.96.36.199 Regulatory Guidelines
188.8.131.52 Reimbursement issues
4.3.3 Market Opportunities
184.108.40.206 Potential radioisotopes in pipeline
220.127.116.11 Increasing neurological applications
18.104.22.168 Cyclotron based production
22.214.171.124 Shutdown of Nuclear reactors
5. Market Segmentation
5.1 Therapeutic Market
5.1.1 Beta Emitters
126.96.36.199 Iodine-131 (I-131)
188.8.131.52 Yttrium-90 (Y-90)
184.108.40.206 Samarium-153 (SM-153)
220.127.116.11 Rhenium-186 (RE-186)
18.104.22.168 Lutetium-177 (LU-177)
5.1.2 Alpha Emitters
22.214.171.124 Radium-223 (RA-223) & Alpharadin
126.96.36.199 Actinium-225 (AC-225)
188.8.131.52 Lead-212 (PB-212)/Bismuth-212 (BI-212)
184.108.40.206 Astatine-211 (AT-211)
220.127.116.11 Radium-224 (RA-224)
18.104.22.168 Thorium-227 (TH-227)
5.2 Therapeutic Application
5.2.2 Bone Metastasis
5.2.4 Endocrine Tumors
5.3 By Geography
5.3.1 North America
6. COMPETITIVE LANDSCAPE
6.1 Acquisitions and mergers
6.2 New product launch
6.3 Agreements and collaborations
7. Company Profiles
7.1 IBA Group
7.2 Lantheus Medical Imaging
7.3 Triad Isotopes
7.4 Siemens Healthcare (PETNET Solutions)
7.5 NTP Radioisotopes